TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03508999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Description: The application of metronidazole gel is effective in the management of gingivitis in patients undergoing orthodontic therapy. Additionally, the constant reminder therapy at weekly interval would also lead to improvement in the oral hygiene.16 According to pertinent literature survey, none of the study has been conducted to compare the effectiveness of SMS reminders and use of anaerobic gel to reduce gingival inflammation.
Study: NCT03481374

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: autonomic function testing
Description: autonomic function testing, ergospirometry, three questionnaires~Other Names:~* The autonomic function tests consist of five tests:~  * The Valsalva maneuver~ * The isometric handgrip test~ * The deep breathing test~ * The cold pressor test~ * A short head-up tilt test~* A maximal ergospirometry~* Three questionnaires:~  * EQ-5D-3L: quality of life~ * IPAQ: capacity to do physical activities

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: autonomic function testing
Description: autonomic function testing, ergospirometry, three questionnaires~Other Names:~* The autonomic function tests consist of five tests:~  * The Valsalva maneuver~ * The isometric handgrip test~ * The deep breathing test~ * The cold pressor test~ * A short head-up tilt test~* A maximal ergospirometry~* Three questionnaires:~  * EQ-5D-3L: quality of life~ * IPAQ: capacity to do physical activities
Study: NCT02486640

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaferon, BAY86-5046)
Description: Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.

Intervention type: DEVICE
Intervention: Betaconnect Autoinjector
Description: Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
Study: NCT00669643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PB 6 doses - Rifampicin and Dapsone
Description: Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;~Children: 6 doses;~1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 6 doses - Rifampicin, Clofazimine and Dapsone
Description: Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 6 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB 12 doses - Rifampicin, Clofazimine and Dapsone
Description: Adult: 12 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 12 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB 6 doses - Rifampicin, Clofazimine and Dapsone
Description: Adult: 6 doses~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine~Children: 6 doses~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine
Study: NCT03577977

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)
Description: Betaferon was injected subcutaneously as prescribed by the treating physician.
Study: NCT00065637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Synthetic human parathyroid hormone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo teriparatide
Description: Placebo injections
Study: NCT03590535

Intervention type: DIAGNOSTIC_TEST
Intervention: 4th Gen cTnT
Description: Current Fourth Generation Cardiac Troponin T Enzyme Assay

Intervention type: DIAGNOSTIC_TEST
Intervention: 5th Gen cTnT
Description: New Fifth Generation (High-sensitivity) Troponin T Enzyme Assay
Study: NCT03508999

Intervention type: OTHER
Group type: OTHER
Intervention: SMS text reminder
Description: Subjects will be provided biweekly reminder via 'SMS text reminder' in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
Study: NCT01183702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK surgery
Description: Participants have received LASIK surgery and their eyes are healthy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Participant has healthy eyes not altered by LASIK surgery.
Study: NCT01188876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given intravenously on Day 1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate
Description: Given intravenously on Day 1 and Day 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Given orally on a daily basis starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12 Injection
Description: Given vitamin B12 injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks after the first dose of pralatrexate.
Study: NCT01113645

Intervention type: PROCEDURE
Intervention: Cerebral perfusion evaluation
Description: The patient who received a craniectomy is included in the study and an information notice given to him. All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores 1 week prior and 6 and 24 weeks post cranioplasty. Furthermore, hemodynamic monitoring is performed by CT perfusion scan (with quantitative assessment of global and local cerebral flow) 1 week prior and 6 weeks post cranioplasty, as well as by trans-cranial Doppler 1 week prior and 6 and 24 weeks post cranioplasty.
Study: NCT01490606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knee OA project
Description: physical therapy in OA Knee project, total of 12 sessions, 6 group therapies amd 6 one on one therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional PT
Description: 12 SESSIONS OF CONVENTIONAL PHYSICAL THERAPY
Study: NCT00614120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg/day, s.c. (under the skin) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Glimepiride placebo, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Glimepiride placebo, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Glimepiride placebo, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.2 mg/day, s.c. (under the skin) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg/day, s.c. (under the skin) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: Capsules, 4.0 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1.5-2.0 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1.5-2.0 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1.5-2.0 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, 1.5-2.0 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo, s.c. (under the skin) injection
Study: NCT00923182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Study: NCT03722745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARGET
Description: TARGET is manualized cognitive-behavioral treatment designed to help adolescents and adults with symptoms of posttraumatic stress

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: It involves referral to an offsite community mental health provider with no attempt to control the treatment modality-type-quality (i.e., evidence-based-treatment or not).
Study: NCT00746824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM30339 and/or placebo
Description: The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM30339 and/or placebo
Description: The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM30339 and/or placebo
Description: The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM30339 and/or placebo
Description: The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM30339 and/or placebo
Description: The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM30339 and/or placebo
Description: The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
Study: NCT00721344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder (FDKP)
Description: Technosphere® Inhalation Powder 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder (FDKP)
Description: Technosphere® Inhalation Powder 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder (FDKP)
Description: Technosphere® Inhalation Powder 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder (FDKP)
Description: Technosphere® Inhalation Powder 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Tablets 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Tablets 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Tablets 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Tablets 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder (FDKP)
Description: Technosphere® Inhalation Powder 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder (FDKP)
Description: Technosphere® Inhalation Powder 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder (FDKP)
Description: Technosphere® Inhalation Powder 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Inhalation Powder (FDKP)
Description: Technosphere® Inhalation Powder 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cartridges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cartridges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cartridges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cartridges
Study: NCT03439540

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plantago major
Description: Individuals receive Plantago major daily, for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals receive placebo daily, for 12 weeks
Study: NCT04487483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep App
Description: A sleep app offering 6 evidence based techniques to improve sleep (such as Cognitive Behavioural Therapy for Insomnia, Progressive Muscle Relaxation and Mindfulness Meditation), allowing for a personally tailored journey of sleep aids within the app.
Study: NCT02083055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: controlled hypotensive anesthesia with dexmedetomidine compare with nitroglycerin on anesthetic outcome such as analgesic use, time to eye opening, follow verbal command, extubation and early postoperative pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: controlled hypotensive anesthesia with nitroglycerin compared with dexmedetomidine on anesthetic outcomes such as analgesic use, time to eye opening, follow verbal command, extubation, and early postoperative pain.
Study: NCT01594892

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery
Study: NCT04097795

Intervention type: OTHER
Intervention: Prehabilitation
Description: According to our definition, prehabilitation consists of exercise therapy during at least 2 weeks. This is combined with optimalisation of the patients' nutritional status at least 2 weeks before surgery.
Study: NCT00725608

Intervention type: DRUG
Intervention: buprenorphine/naloxone
Description: 2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months
Study: NCT02048917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + Long Acting NRT + PRN NRT
Description: High Intensity Counseling + Long Acting NRT + PRN NRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + bupropion + PRN NRT
Description: High Intensity Counseling + bupropion + PRN NRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + varenicline + PRN NRT
Description: High Intensity Counseling + varenicline + PRN NRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + Long Acting NRT
Description: High Intensity Counseling + Long Acting NRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + bupropion
Description: High Intensity Counseling + bupropion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Intensity Counseling + varenicline
Description: High Intensity Counseling + varenicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + Long Acting NRT + PRN NRT
Description: Low Intensity Counseling + Long Acting NRT + PRN NRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + bupropion + PRN NRT
Description: Low Intensity Counseling + bupropion + PRN NRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + varenicline + PRN NRT
Description: Low Intensity Counseling + varenicline + PRN NRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + Long Acting NRT
Description: Low Intensity Counseling + Long Acting NRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + bupropion
Description: Low Intensity Counseling + bupropion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Intensity Counseling + varenicline
Description: Low Intensity Counseling + varenicline
Study: NCT03676114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 0.5mg/kg intravenous ketamine injection before incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Same volume of normal saline will be administrated
Study: NCT02648477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02215863

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad and Prevenar13

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Study: NCT03249597

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test: Glukos, SuPAR, Laktat and HBP
Description: Four blood tests described in the section Biospecimen Description are analyzed within the main study; Glukos, SuPAR, Laktat and HBP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test: Glukos, SuPAR, Laktat and HBP
Description: Four blood tests described in the section Biospecimen Description are analyzed within the main study; Glukos, SuPAR, Laktat and HBP.
Study: NCT00108485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended release niacin
Description: Extended release niacin 1500-2000mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT03358771

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COPD discharge care bundle
Description: As a part of RHSCN quality improvement initiative, the elements of the COPD discharge bundle were integrated into a standardized COPD admission order set and are being implemented province-wide. The discharging physician/team will complete the COPD bundle (with reminders facilitated by clinical decision support tools) prior to patient discharge. A copy of the bundle is retained in the patient's medical record, and another copy is sent to the patient's primary care provider detailing the components of the bundle that were completed prior to discharge, and those still needing to be addressed. The patient will also receive a patient-focused discharge checklist detailing discharge bundle items

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD discharge care bundle & coordinator
Description: The coordinator will be health professional associated with a Primary Care Network, ED or AHS with access to patient information. Patients will be informed that care coordinator may contact them for follow up after discharge. At 48-72 hours after hospital/ED discharge and then at intervals to be determined, the care coordinator will contact the patient by phone. The care coordinator will identify specific needs or problems that patient may have encountered after discharge, which could potentially affect the successful transition from acute to community care setting. Specifically, the care coordinator will seek information on any follow up with family doctor visit, pulmonary rehabilitation and smoking cessation referrals
Study: NCT02545361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAHR-102
Description: KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~Planned doses for stage 1:~Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days).